Oncology

November 30, 2020

The continuous battle in cancer research has unfortunately fallen a bit to the backseat due to healthcare's main focus on beating COVID-19 wildfires. To bring its needed attention back up on the ladder, Marie Lamont, president and COO of Inteliquet, a clinical trial software company, shares what took place in the drop of oncology-related activity and what can be done to improve.

November 29, 2020

FDA approves several drugs to treat rare conditions in both cancer and metabolic diseases.

November 27, 2020

Public health policies and treatment advances have made a difference.

November 26, 2020

Radiation oncologists across the country met virtually with members of Congress last week to urge lawmakers to pass legislation that will safeguard access to high-quality, value-based healthcare for people with cancer.

November 24, 2020

Therapies that target lung cancer at the molecular level are proliferating — and so are the biomarkers for guiding their use.

November 23, 2020

In the early going, patients seeking the expensive, customized cancer treatments called CAR-T cell therapy had to go to an academic medical center. But that’s changing, as Duncan Allen, M.H.A., of the community cancer network OneOncology explains.

November 20, 2020

Two newly approved antibody-drug conjugates and changes in radiation therapy lead the way.

November 02, 2020

The Johns Hopkins professor and new MHE editorial advisory board member discusses screening among race, how certain screening tests intensify health disparities and how the Trump administration is not correctly applying science within healthcare in this final part of a four-part video series.

November 01, 2020

FDA approves new uses for companion diagnostics, while Janssen seeks a new indication for Xarelto.

October 25, 2020

Gilead's Veklury gets full approval; AstraZeneca's Tagrisso heads toward second indication in NSCLC; another use for experimental antifungal therapy.